Transfusion Triggers for Platelets and Other Blood Products

Sunil Karanth

Indian Journal of Critical Care Medicine (2019): 10.5005/jp-journals-10071-23250

INTRODUCTION

Transfusion of whole blood is not associated with any significant benefit, rather can be harmful. Significant advances have been made in transfusion medicine, facilitating the use of blood product or component therapy than use of whole blood (Fig. 1). In 2009, a report on Serious Hazards of Transfusion in the UK, estimated that a total of 3 million units of blood components were released. The requirement of the same in South-East Asia is much higher to the tune of 15 million units annually. The current recommendation is to use blood only in life-threatening situations, rather than to normalize abnormal numbers.

PLATELETS

Platelets are derived from the buffy coat of whole blood donations. A pooled platelet concentrate includes pooled buffy-coat derived platelets from four whole-blood donations suspended in platelet additive solution and plasma of one of the four donors. It contains 240000 platelets pooled from 4–6 donors. A Single donor platelet is derived from a single-donor by a process of apheresis. In view of the lesser number of donors and the theoretical advantage of involving a single-donor platelet (SDP) may be preferred over the use of platelets from multiple donors. A SDP may contain at least 55000 platelets.

Some of the important characteristics of platelet transfusions include storage at 20–24 degree Centigrade (°C) with constant agitation for 5 days, the need to be transfused within 4 hours of collection, at a rate not less than 30 minutes. Based on the various indications and available guidelines, the following are the indications for transfusion of platelets:

- Active bleeding in the presence of platelet defects.
- Platelet count of <50000/mm³ in patients with active bleeding.
- In hematology patients having active bleeding associated with dengue, malaria, kalaazar and autoimmune platelet disorders.
- In oncology patients:
  - Patients with platelet counts <20000/mm³ in the presence of risk factors.
  - Patients with platelet counts <10000/mm³ with no risk factors.
- In patients needing surgical or any other interventions:
  - Platelet count <50000/mm³, if there is minimal risk of bleeding
  - Platelet <100000/mm³, for any ophthalmic or central nervous system surgeries.
- Part of massive transfusion protocol as specific blood component therapy.
- In severe uncontrolled bleeding, postcardiopulmonary by pass.

FRESH FROZEN PLASMA

Fresh Frozen Plasma (FFP) is the liquid part of the blood obtained after separation of the cellular part of the blood. The separated liquid part is immediately frozen. FFPs have a volume of 200–300 mL, frozen to a temperature of −25°C within 6 hours, to ensure activity of the coagulation factors. FFPs can be stored for up to one year at a temperature of −25°C. However, prior to administration, FFPs would be needed to be thawed, and need to be used within 30 minutes of thawing. FFPs primarily contain stable clotting factors, albumin and Immunoglobulins. Generally, the dose of FFPs ranges 10–15 mL/kg. The target INR is 1.7, prothrombin time (PT) <1.5 or a activated Prothrombin time (APTT) of less than twice the normal. Transfusions of FFPs are indicated in the following clinical situations:

- Presence of laboratory proven coagulopathy with active bleeding. Laboratory proven includes PT >1.5, INR >2 and aPTTT > twice the normal limit.
- Emergency reversal of Warfarin effect, especially if there is need for an urgent surgery or when there is ongoing active bleeding.
- Dilutional coagulopathy – having a procedure or in the presence of active bleeding.
- Liver disease with coagulopathy in the presence of active bleeding or needing an intervention.

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
• Prophylaxis in patients with coagulopathy undergoing surgery or other invasive procedures.
• Replacement of single factor deficiencies namely, factors V and XI.

CRYOPRECIPITATE

Cryoprecipitate is the fraction of the liquid part of the blood (plasma), which is undissolved following thawing of the plasma. Cryoprecipitate contains fibrinogen (150–300 mg/pack), factor VIII (80–100 IU/pack), von Willebrand factor and fibrinectin. Similar to FFPs, cryoprecipitate packs can be stored at -25° C for up to one year. The thawed product needs to be used within 6 hours of thawing. The indications for the transfusion of Cryoprecipitate include the following:
• Fibrinogen levels <100 mg/dL in patients with bleeding
• Massive transfusion
• Factor XIII deficiency
• Liver disease in the presence of active bleeding
• Disseminated intravascular coagulation (DIC) in the presence of active bleeding.

FACTOR CONCENTRATES

Individual factor concentrates are available as replacement products for a few specific factors. However, high costs and limited availability have not made these products popular as a routine modality of therapy. In a community setting, specific factor concentrates are used in the management of hemophilia patients. Some of the clinical significant factor concentrates include:
• Recombinant or plasma-derived factor VIII: The use of this factor is recommended in the treatment of moderate to severe hemophilia A (factor VIII deficiency). In mild deficiency, it is usually not required, unless unresponsive to desmopressin. Recombinant or plasma-derived factor IX deficiency: It is recommended in the treatment of hemophilia B (factor IX deficiency)
• Activated prothrombin complex concentrates: It is used for bleeding episodes or prior to surgical procedures in patients with hemophilia A or B, if individual components or factors are not available. They are also recommended in the presence of inhibitors to native coagulation factors.
• Prothrombin complex concentrates: It comes as four-factor concentrates containing factors II, VII, IX and X, with protein S, C and heparin. It is used for urgent reversal of warfarin in a situation of a life-threatening bleeding or in the setting of deficiencies of other vitamin-K dependent factors, where obtaining specific factors may be practically difficult.

REFERENCES